These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 32385248)

  • 1. Structural basis for impairment of DNA methylation by the DNMT3A R882H mutation.
    Anteneh H; Fang J; Song J
    Nat Commun; 2020 May; 11(1):2294. PubMed ID: 32385248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The DNMT3A R882H mutant displays altered flanking sequence preferences.
    Emperle M; Rajavelu A; Kunert S; Arimondo PB; Reinhardt R; Jurkowska RZ; Jeltsch A
    Nucleic Acids Res; 2018 Apr; 46(6):3130-3139. PubMed ID: 29518238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutations of R882 change flanking sequence preferences of the DNA methyltransferase DNMT3A and cellular methylation patterns.
    Emperle M; Adam S; Kunert S; Dukatz M; Baude A; Plass C; Rathert P; Bashtrykov P; Jeltsch A
    Nucleic Acids Res; 2019 Dec; 47(21):11355-11367. PubMed ID: 31620784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The R882H DNMT3A hot spot mutation stabilizes the formation of large DNMT3A oligomers with low DNA methyltransferase activity.
    Nguyen TV; Yao S; Wang Y; Rolfe A; Selvaraj A; Darman R; Ke J; Warmuth M; Smith PG; Larsen NA; Yu L; Zhu P; Fekkes P; Vaillancourt FH; Bolduc DM
    J Biol Chem; 2019 Nov; 294(45):16966-16977. PubMed ID: 31582562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural basis for DNMT3A-mediated de novo DNA methylation.
    Zhang ZM; Lu R; Wang P; Yu Y; Chen D; Gao L; Liu S; Ji D; Rothbart SB; Wang Y; Wang GG; Song J
    Nature; 2018 Feb; 554(7692):387-391. PubMed ID: 29414941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The R882H DNMT3A mutation associated with AML dominantly inhibits wild-type DNMT3A by blocking its ability to form active tetramers.
    Russler-Germain DA; Spencer DH; Young MA; Lamprecht TL; Miller CA; Fulton R; Meyer MR; Erdmann-Gilmore P; Townsend RR; Wilson RK; Ley TJ
    Cancer Cell; 2014 Apr; 25(4):442-54. PubMed ID: 24656771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The DNMT3A R882H mutation does not cause dominant negative effects in purified mixed DNMT3A/R882H complexes.
    Emperle M; Dukatz M; Kunert S; Holzer K; Rajavelu A; Jurkowska RZ; Jeltsch A
    Sci Rep; 2018 Sep; 8(1):13242. PubMed ID: 30185810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNMT3A(R882H) mutant and Tet2 inactivation cooperate in the deregulation of DNA methylation control to induce lymphoid malignancies in mice.
    Scourzic L; Couronné L; Pedersen MT; Della Valle V; Diop M; Mylonas E; Calvo J; Mouly E; Lopez CK; Martin N; Fontenay M; Bender A; Guibert S; Dubreuil P; Dessen P; Droin N; Pflumio F; Weber M; Gaulard P; Helin K; Mercher T; Bernard OA
    Leukemia; 2016 Jun; 30(6):1388-98. PubMed ID: 26876596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-guided functional suppression of AML-associated DNMT3A hotspot mutations.
    Lu J; Guo Y; Yin J; Chen J; Wang Y; Wang GG; Song J
    Nat Commun; 2024 Apr; 15(1):3111. PubMed ID: 38600075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional Analysis of DNMT3A DNA Methyltransferase Mutations Reported in Patients with Acute Myeloid Leukemia.
    Khrabrova DA; Loiko AG; Tolkacheva AA; Cherepanova NA; Zvereva MI; Kirsanova OV; Gromova ES
    Biomolecules; 2019 Dec; 10(1):. PubMed ID: 31861499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of
    Tabatabaei T; Rezvany MR; Ghasemi B; Vafaei F; Zadeh MK; Zaker F; Salmaninejad A
    Biomed Res Int; 2024; 2024():9625043. PubMed ID: 38807916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNMT3A R882H mutation promotes acute leukemic cell survival by regulating glycolysis through the NRF2/NQO1 axis.
    Chu X; Zhong L; Dan W; Wang X; Zhang Z; Liu Z; Lu Y; Shao X; Zhou Z; Chen S; Liu B
    Cell Signal; 2023 May; 105():110626. PubMed ID: 36758683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNMT3A R882H mutation drives daunorubicin resistance in acute myeloid leukemia via regulating NRF2/NQO1 pathway.
    Chu X; Zhong L; Dan W; Wang X; Zhang Z; Liu Z; Lu Y; Shao X; Zhou Z; Chen S; Liu B
    Cell Commun Signal; 2022 Oct; 20(1):168. PubMed ID: 36303144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA methyltransferase DNMT3A forms interaction networks with the CpG site and flanking sequence elements for efficient methylation.
    Dukatz M; Dittrich M; Stahl E; Adam S; de Mendoza A; Bashtrykov P; Jeltsch A
    J Biol Chem; 2022 Oct; 298(10):102462. PubMed ID: 36067881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CpG Island Hypermethylation Mediated by DNMT3A Is a Consequence of AML Progression.
    Spencer DH; Russler-Germain DA; Ketkar S; Helton NM; Lamprecht TL; Fulton RS; Fronick CC; O'Laughlin M; Heath SE; Shinawi M; Westervelt P; Payton JE; Wartman LD; Welch JS; Wilson RK; Walter MJ; Link DC; DiPersio JF; Ley TJ
    Cell; 2017 Feb; 168(5):801-816.e13. PubMed ID: 28215704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetic Perturbations by Arg882-Mutated DNMT3A Potentiate Aberrant Stem Cell Gene-Expression Program and Acute Leukemia Development.
    Lu R; Wang P; Parton T; Zhou Y; Chrysovergis K; Rockowitz S; Chen WY; Abdel-Wahab O; Wade PA; Zheng D; Wang GG
    Cancer Cell; 2016 Jul; 30(1):92-107. PubMed ID: 27344947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preferential Self-interaction of DNA Methyltransferase DNMT3A Subunits Containing the R882H Cancer Mutation Leads to Dominant Changes of Flanking Sequence Preferences.
    Mack A; Emperle M; Schnee P; Adam S; Pleiss J; Bashtrykov P; Jeltsch A
    J Mol Biol; 2022 Apr; 434(7):167482. PubMed ID: 35131259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The R882H substitution in the human
    Sandoval JE; Reich NO
    J Biol Chem; 2019 Nov; 294(48):18207-18219. PubMed ID: 31640986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AML-Associated Mutations in DNA Methyltransferase DNMT3A.
    Khrabrova DA; Yakubovskaya MG; Gromova ES
    Biochemistry (Mosc); 2021 Mar; 86(3):307-318. PubMed ID: 33838631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. XPO1 inhibition displays anti-leukemia efficacy against DNMT3A-mutant acute myeloid leukemia via downregulating glutathione pathway.
    Cai X; Liu Y; Li H; Que Y; Xiao M; Wang Y; Wang X; Li D
    Ann Hematol; 2024 Jul; 103(7):2311-2322. PubMed ID: 38519605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.